Wells Fargo Maintains Overweight on RxSight, Lowers Price Target to $54
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Larry Biegelsen maintains an Overweight rating on RxSight (NASDAQ:RXST) but lowers the price target from $68 to $54.
August 06, 2024 | 3:10 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Wells Fargo analyst Larry Biegelsen maintains an Overweight rating on RxSight but lowers the price target from $68 to $54.
The lowered price target from $68 to $54 suggests a less optimistic outlook for RxSight's stock performance, which could lead to a short-term negative impact on the stock price despite the maintained Overweight rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100